SKYE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
11.1M
-12.7%
12.7M
-14.9%
14.9M
+12.3%
13.3M
-27.3%
18.2M
R&D
3.9M
-50.3%
7.9M
-30.8%
11.5M
+22.6%
9.4M
-34.7%
14.3M
SG&A
3.9M
-18.3%
4.7M
+38.3%
3.4M
-12.3%
3.9M
+0.0%
3.9M
Operating Income
-11061303
+12.7%
-12674366
+14.9%
-14895544
-12.3%
-13264534
+27.3%
-18243925
EBITDA
-10903705
+12.8%
-12501480
+15.0%
-14715535
-12.5%
-13085636
+27.5%
-18056859
Net Income
-10786594
+13.8%
-12509361
+13.4%
-14441963
-13.2%
-12754660
+27.6%
-17624872
EPS (Basic)
$-2.16
+15.6%
$-2.56
+12.0%
$-2.91
-13.7%
$-2.56
+27.3%
$-3.52
EPS (Diluted)
$-2.16
+15.6%
$-2.56
+12.0%
$-2.91
-13.7%
$-2.56
+27.3%
$-3.52
Shares (Diluted)
5.0M
+0.0%
5.0M
+0.0%
5.0M
+0.0%
5.0M
+0.0%
5.0M
Skye Bioscience (SKYE) โ€” Financials